logo-loader
viewAdalta Ltd

AdAlta capitalises on $5-million raising to progress drug to treat fibrotic diseases

AdAlta Ltd (ASX:1AD) chief executive officer Sam Cobb updates Proactive Investors on the health-focused company's recent $5 million raising to progress the development of its key AD-214 drug for the treatment of idiopathic pulmonary fibrosis.
 
Cobb says recent animal trials will soon progress to human testing in Australia.
 
The company aims to start phase-one studies in January 2020.

Quick facts: Adalta Ltd

Price: 0.12 AUD

ASX:1AD
Market: ASX
Market Cap: $19.72 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Adalta Ltd named herein, including the promotion by the Company of Adalta Ltd in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

AdAlta targeting human trials for lead i-body fibrosis candidate in under a year

AdAlta Ltd (ASX: 1AD) CEO Sam Cobb speaks to Proactive Investors about the biotech's i-body technology platform and pipeline of i-bodies; including its lead candidate for treating fibrotic diseases, in particular Idiopathic Pulmonary Fibrosis, AD-214. A phase I human study is expected to...

on 18/2/19

2 min read